Back to search
FDAFDA · Food and drugs·Recall number D-0720-2021

Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01

Published August 18, 2021 · Recall initiated: June 29, 2021

Summary

FDA records drug Class II recall D-0720-2021, published August 18, 2021 and initiated June 29, 2021. Recalling firm: Eli Lilly & Company; Status: Terminated; Reported quantity: 36,540 vials; Lot: Lot # 197. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Eli Lilly & Company
Distributor
OH, MS, IN
Lot
Lot # 197
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01 recalled?

Yes. FDA published recall D-0720-2021 on August 18, 2021. Reported hazard: cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter